Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis
Launched by WAKE FOREST UNIVERSITY · Sep 13, 2005
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Smokers (past or current,20 pack years) with diagnosis of chronic bronchitis
- • expectorate sputum daily
- • FEV1 of 40-70%
- • understand and fill out questionnaire daily
- Exclusion Criteria:
- • other investigational within 30 days
- • change in smoking habit within 6 months
- • pulmonary diagnosis other that chronic bronchitis
- • significant renal, cardiac, hepatic or endocrine diseases
- • psychiatric disorder or evidence of alcoholism or drug abuse within year
About Wake Forest University
Wake Forest University is a leading academic institution known for its commitment to innovative research and excellence in education. The university's clinical trial sponsor arm focuses on advancing medical knowledge and improving patient care through rigorous clinical investigations. With a multidisciplinary team of experienced researchers and healthcare professionals, Wake Forest University engages in a wide range of clinical studies that span various therapeutic areas. The institution emphasizes ethical practices, participant safety, and collaboration with industry and regulatory bodies to ensure the integrity and success of its clinical trials. Through its robust research infrastructure, Wake Forest University aims to translate scientific discoveries into effective clinical solutions, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winston Salem, North Carolina, United States
Patients applied
Trial Officials
Bruce K Rubin, MEng,MD,MBA
Principal Investigator
Wake Forest University Health Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials